Royal Bank Of Canada Downgrades Telix Pharmaceuticals (NASDAQ:TLX) to Sector Perform

Telix Pharmaceuticals (NASDAQ:TLX) was downgraded by analysts at Royal Bank Of Canada from an “outperform” rating to a “sector perform” rating in a report released on Friday, Marketbeat Ratings reports.

TLX has been the topic of several other research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Monday, April 20th. Wedbush restated an “outperform” rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Monday, July 6th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a report on Tuesday, July 7th. Citigroup decreased their target price on Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Finally, Wall Street Zen raised Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, April 11th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.40.

Telix Pharmaceuticals Trading Down 4.1%

Shares of NASDAQ:TLX opened at $10.83 on Friday. The firm has a fifty day moving average price of $10.36 and a 200 day moving average price of $9.05. Telix Pharmaceuticals has a fifty-two week low of $6.28 and a fifty-two week high of $16.94. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Insider Buying and Selling at Telix Pharmaceuticals

In other Telix Pharmaceuticals news, CEO Christian Behrenbruch bought 33,435 shares of Telix Pharmaceuticals stock in a transaction dated Wednesday, April 29th. The shares were purchased at an average cost of $14.87 per share, for a total transaction of $497,178.45. Following the acquisition, the chief executive officer directly owned 20,742,935 shares in the company, valued at approximately $308,447,443.45. This represents a 0.16% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Rhumbline Advisers grew its position in Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after acquiring an additional 1,392 shares in the last quarter. Bank of America Corp DE raised its position in Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after purchasing an additional 8,423 shares during the period. XTX Topco Ltd purchased a new stake in Telix Pharmaceuticals during the fourth quarter valued at approximately $89,000. XY Capital Ltd bought a new stake in shares of Telix Pharmaceuticals in the 1st quarter valued at approximately $120,000. Finally, IHT Wealth Management LLC bought a new stake in shares of Telix Pharmaceuticals in the 2nd quarter valued at approximately $213,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.